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1. Introduction
Nuclear medicine therapy is required to be highly specific and targeted since it always involves
administration of unsealed sources of radioactivity. Radionuclides emitting ß-particles are
generally used for therapeutic purposes because of their ability to penetrate and depositing
cytotoxic energy in tissues. There are several choices of ß emitters with respect to energy of
the emission. Lower energy ß particles can travel a few cell diameters, or at most in the sub-
millimeter range, whereas higher energy ß particles such as those emitted by yittrium 90 (90Y)
have a greater tissue penetration with a range beyond the source of several millimeters. The
physical half-life of the therapeutic radionuclide is also an important consideration and
underlying principle for therapy planning. For therapeutic purposes, radionuclides are
usually, except in thyroid treatment, attached to a drug or particle that controls the biodistri‐
bution. The ideal therapeutic radiopharmaceutical is one that remains attached to the parent
drug or its metabolites, and is excreted rapidly through a known simple route[1].
1.1. Concepts and principles
Along with the significant progress in hepatobiliary surgery in the last 30 years, various
innovative liver-directed treatments have been developed [2] including conformal radiation,
hepatic  arterial  infusion  chemotherapy  (HAI),  transarterial  chemoembolization  (TACE),
radiofrequency ablation (RFA) and radioembolization (RE) with radionuclide microspheres [3].
Conformal and stereotactic radiation therapy techniques can be used to deliver high radiation
doses in cases with focal involvement [4]; however, since hepatic primary neoplasms are often
multifocal and irregular in shape, and potentially replacing large parts of the liver volume,
only a small minority of patients are optimal candidates for such therapies[5].
© 2013 Ahmadzadehfar et al.; licensee InTech. This is an open access article distributed under the terms of
the Creative Commons Attribution License (http://creativecommons.org/licenses/by/3.0), which permits
unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
Radioembolization (RE), also named selective internal radiation therapy (SIRT), is a promising
catheter based liver-directed modality for patients with primary and metastatic liver cancer.
RE provides several advantages over traditional treatment methods including its low toxicity
profile[6, 7].
Its rationale arises from the anatomic and physiological aspects of hepatic tumors being
exploited for the delivery of therapeutic agents. The prominent feature is the dual blood supply
of liver tissue, from the hepatic artery and the portal vein. Observations on vascular supply to
hepatic malignancies have demonstrated that metastatic hepatic tumors >3 mm derive 80–
100% of their blood supply from the arterial rather than the portal hepatic circulation[8].
Normal liver tissue, in contrary, is predominantly fed by the portal vein (60-70%). Apart from
RE with 90Y microspheres, being an approved therapy by the Food and Drug Administration
(FDA), various other radionuclides has also been used or investigated for treatment of liver
tumors including Phosphorus-32, Rhenium-188 and holmium-166[9-12]. In this chapter,
however, we focus only on the therapeutic indications, usefulness and methods of treatment
with 90Y-microspheres.
1.2. Physical characteristics of 90Y and microspheres
90Y is a pure β emitter, produced by neutron bombardment of yttrium-89 in a reactor, with a
limited tissue penetration (mean 2.5 mm, max 11 mm), and short half-life (64 h), making it an
ideal transarterial liver-directed agent. The size of the microspheres ranges between 20-40 µm.
The upper size limit of the microspheres allows delivery to the tumours via the hepatic artery,
while the lower size limit prevents the microspheres from passing from the arterial circulation
into the venous circulation. The microspheres remain trapped within the vasculature of the
tumours and deliver a selective radiation dose to the tumour tissue [13].
The mean tissue penetration of 2.5 mm of ß particles emitted from the selectively delivered
yttrium allows an extremely high local tumour doses ranging from 50 to 150 Gy [14-17] to >
1000 Gy to the tumour tissue while sparing normal liver parenchyma. This is in contrast to
traditional whole liver external beam radiation where radiation doses have to be limited to 30
Gy to prevent serious hepatic dysfunction [18].
Two 90Y microsphere products are commercially available: TheraSphere® (glass micro‐
spheres) and Sirsphere® (resin microsphere). There are some distinct differences in properties
between the two products as shown in Table 1.
1.3. Patient selection criteria
The selection process of patients referred for RE involves several aspects to be taken into account.
Patients considered for RE should have especially (1) unresectable hepatic tumour, (2) liver-
dominant tumour burden, (3) a life expectancy of at least 3 months and (4) an ECOG perform‐
ance score of ≤2[19]. The general clinical condition, as described by the ECOG or Karnofsky
performance score is an important aspect for patient selection prior to RE. Patients with a
significantly reduced performance status are at higher risk of developing severe side effects,
including radiation induced liver failure[20, 21] and generally have worse treatment outcome.
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These lead to questioning the rationale of posing the patient at such costly and potentially harmful
treatment measure. Contraindications for RE include pretreatment angiogram indications of
flow to the gastrointestinal tract which can not be corrected by coilc embolization techniques,
an excessive shunting to the lungs that would result in > 30 Gy lung dose on a single administra‐
tion as quantified by the tc-99m macroaggregated albumin (Tc-MAA) scan, excessive tumour
burden with limited hepatic reserve, and biochemical evidence of reduced liver function as
potentially indicated by elevated levels of bilirubin (widely suggested cut-off: 2 mg/dl), highly
elevated liver enzymes (AST or ALT > 5x upper normal limit), significantly altered INR or PTT,
or reduced serum albumin. Patients with prior radiotherapy involving the liver should be
carefully reviewed on a case-by-case basis (Table 2) [7, 19].
1. Absent surgical (resection, liver transplantation) or ablative options (RFA)
2. Preserved liver function (intact liver synthesis)
a Bilirubin (< 2 mg/dl)
b. Albumin (≥ 3 mg/dl)
c. PT/PTT (no endogenous severe impairment)
d. AST/ALT ≤ 5 x normal
3. Adequate general condition (ECOG performance score ≤ 2)
4. Liver-dominant tumor burden
5. Life-expectancy ≥ 3 months
6. Acceptable LSF (≤20% for resin and ≤30Gy for glass microspheres)
Table 2. Basic requirements for radioembolization
Y90 microspheres SIR-Spheres TheraSphere
Company Sirtex Medical, Sydney,Australia
MDS Nordion, Ottawa,
Ontario, Canada
material resin-based glass-based
Diameter 20–60 µm 20–30 µm
Activity per particle 50 Bq 2500 Bq
Number of microspheres
per 3-GBq vial 40–80 X 106 1.2 X 106
Specific gravity 1.6 g/mL 3.2 g/mL
Maximal prescribed dose (GBq) 3 20
Relative embolic potential Higher Lower
Relative pressure for infusion Lower Higher
Contrast injection during infusion possible Not possible
Table 1. Properties of resin and glass yttrium-90 microspheres
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The renal status should be adequate to accommodate for any concurrent chemotherapy that
is part of the treatment plan[22], as well as for the use of contrast agents during the diagnostic
and the therapeutic angiogram. Hemodialysis patients may be treated with RE, however,
dialysis has to be planned and timed before and after the intervention.
The decision to perform RE should be based on an interdisciplinary consent, ideally after
discussion in an adequate tumor board with participation of specialists in surgery, gastroen‐
terology, oncology, radiology, nuclear medicine and radiation therapy. Especially patients not
fulfilling the common inclusion criteria should only be accepted as RE candidates after
appropriate consent from such interdisciplinary tumor board.
1.4. Imaging modalities before radioembolization
The imaging includes a three-phase contrast computed tomography (CT) and/or gadolinium-
enhanced magnetic resonance imaging (MRI) of the liver for assessment of tumour and non-
tumour volume, main portal vein patency, and extent of extrahepatic disease.
18F-Fluorodeoxyglucose positron emission tomography/computed tomography (18F-FDG-
PET/CT) is a very sensitive functional imaging modality for tumours with high glucose
metabolism such as colorectal carcinoma, melanoma, head and neck tumors, and breast cancer.
However, it is not a satisfactory imaging choice for pre- and post treatment evaluation of
patients with HCC as these tumours except for their aggressive types, show no or a very low
grade FDG uptake. This results in the suboptimal sensitivity of 18F-FDG-PET for HCC, ranging
between 50% and 70% [23, 24]. Nevertheless, 18F-FDG-PET may provide prognostic informa‐
tion (metabolic grading) as patients with a negative FDG-PET have a better prognosis than
those with high FDG uptake. Furthermore, addition of a metabolic imaging to the anatomical
imaging modalities before performing RE leads to a more accurate follow up and therapy
response assessment[25].
1.5. Angiogram with selective visceral catheterization and therapy simulation
Once a patient has been selected as a candidate for RE, an initial angiographic evaluation,
known as test-angiogram, has to be performed as the first step, It is well known that the
anatomy of the mesenteric system and the hepatic arterial bed has a high degree of variation,
with “normal vascular anatomy” being present in only 60% of cases. Therefore, in order to
perform any kind of therapeutic transarterial procedure in the liver in a safe and efficient
manner it is essential to be acquainted with the hepatic arterial anatomy[26].
A feature of the neoplastic vasculature within tumours is the formation of arteriovenous
anastomoses or shunts. Shunts allow microspheres to directly enter the venous return by
bypassing the terminal arterioles in the tumour. This will deposit the shunted microspheres
into the lung, resulting in radiation pneumonitis [22, 27].
Dystopic spread of microspheres to other extrahepatic visceral sites such as stomach, duode‐
num or pancreas, may also be associated with the risk of severe radiation damage leading to
pain, ulceration and possibly perforation, pancreatitis, cholecystitis, skin necrosis and other
non-target radiation complications[28].
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Avoiding extrahepatic deposition of microspheres requires prophylactic embolization of all
extrahepatic vessels including the gastroduodenal, right gastric and pancreaticoduodenal
branches. If embolization is not possible, the catheter for treatment can alternatively be placed
beyond the respective origins of these vessels. The angiogram must be accomplished with Tc-
MAA injected into the hepatic artery similar to the application during microsphere treatment
[19]. Scintigraphy should be performed within 1 hour of Tc-MAA injection to prevent false-
positive extrahepatic activity due to free 99mtechnetium (99mTc). The unwanted uptake of 99mTc-
pertechnetate in the thyroid and stomach can be avoided using perchlorate. For this purpose
patients should receive 600 mg perchlorate orally 30 minutes before angiography [29, 30].
It is of note that these vessels/organs can revascularize quickly, and therefore the embolization
should be performed close to the intended time of RE, with a check arteriogram required before
RE to ensure that such revascularization has not occurred[19].
Determining the possibility of lung damage due to liver-to-lung shunting is relatively simple as
described by Lau et al.[31] Following infusion of 100-400 MBq Tc-MAA in the hepatic arterial
branches, a whole body scan in anterior and posterior projections is sufficient to calculate the
percentage of lung shunting and, consequently, the possibility of pulmonary side effects. The
percentage of lung shunting can be determined from the total counts within regions of interest
(ROIs) over both lobes of the lung and the liver, using the geometric mean of ventral and dorsal
images. Depending on the shunt rate, a reduction of the total administered dose to the liver may
be necessary. The highest tolerable dose to the lungs after treatment with RE is considered to be
up to 30 Gy with a single injection, and up to 50 Gy for multiple injections[27]. The estimated
dose (Gy) to the lungs is equal to A (GBq) x LSF x 50, assuming the total mass of both lungs to be
1 kg. Where A is the activity infused and LSF is the lung shunt fraction. The cumulative absorbed
lung radiation dose can be calculated with the following equation [32] [33]:
Cumulative absorbed lung radiation dose= 50 ×  lung mass ∑
i=1
n Ai ×  LSFi
Where Ai = activity infused, LSFi = lung shunt fraction during infusion, n = number of infusions,
and approximate vascular lung mass = 1 kg.
Another way is recommended by SIRTex Company as shown in table 3. According to SIRTex
recommendations, the amount of microspheres delivered to the patient should be reduced if
the lung shunting is more than 10% and RE should not be performed if there is a shunt more
than 20% of the administered dose[22].
Percent Lung Shunting Activity of SIR-Spheres microspheres
<10% Deliver full amount of SIR-Spheres
10% to 15% Reduce amount of SIR-Spheres by 20%
15% to 20% Reduce amount of SIR-Spheres by 40%
>20% Do not give SIR-Spheres microspheres
Table 3. The percent lung shunting may alter the activity that can be safely implanted commensurate with acceptable
risk of radiation pneumonitis.
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Extrahepatic hot spots in Tc-MAA images indirectly mark the possible locations of micro‐
spheres misplaced during therapy. However, detection and accurate localisation of extrahe‐
patic hot spots using only two-dimensional planar scintigraphic images is not always possible,
mainly due to the low spatial resolution. Furthermore, the localization of several different
organs within a relatively small region of upper abdomen demands the analysis of tomo‐
graphic images in order to accurately distinguish whether the Tc-MAA has accumulated in
the liver or in some adjacent organ [30] as planar images cannot always make this distinction
due to organ superposition.
If an extrahepatic tracer accumulation is detected by the Tc-MAA scan, angiogram and coil-
embolization of aberrant arteries should be repeated prior to the RE until no extrahepatic
accumulation is detectable[30]. In this setting, Tc-MAA SPECT/CT imaging has been shown
to provide valuable additional information compared to planar and SPECT images and is the
imaging modality of choice [30, 34, 35]. It significantly increases the sensitivity and negative
predictive value of Tc-MAA scan compared to planar and SPECT alone[30, 34]. The sensitivity,
specificity, positive predictive value and negative predictive value of SPECT/CT in the
diagnosis of abdominal extrahepatic shunting has been found to be as high as100%, 93 %, 89
% and 100 % respectively [30].
2. Dose calculation and therapy planning
In addition to the selective distribution of the microspheres to the liver, the distribution within
the liver plays a critical role in the planning of RE. The treatment should result in low radiation
doses to normal liver tissue and a lethal dose to the tumor tissue. Abnormal high radiation
doses to normal tissue may result in radiation induced hepatitis with potential risk of liver
failure[36].
The required activity for treatment of each patient is to be calculated differently according to
whether glass or resin microspheres are to be used and their significant physical differences
should be considered (Table 1). Selection of the optimal activity of microspheres for an
individual patient is a complex and challenging task. There are some methods for dose
calculation which are briefly introduced here.
2.1. Glass 90Y microsphere activity calculation
TheraSphere® consists of insoluble glass microspheres, where 90Y is an integral constituent of
the glass. The mean sphere diameter ranges from 20 to 30 µm. Each milligram contains between
22,000 and 73,000 microspheres[37].
The dose determination for glass microspheres is based on a nominal average target dose
(80-150 Gy/kg) and the patient's liver mass which determined from the CT or MRI data and
assumes the uniform distribution of the microsphere throughout liver volume as [38]:
A(GBq)glass = D(Gy)×M (Kg)50
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In this equation, A is the activity, D the nominal target dose, and M is the mass of the targeted
liver tissue.
It is recommended that the cumulative lung dose be kept to < 50 Gy to prevent radiation
pneumonitis. The target dose for any given solid tumor is not known; however, it is believed
that doses of 100–120 Gy balance response rates and hepatic fibrosis risk when glass micro‐
spheres are used[19].
When lung shunt fraction and residual activity in the vial after treatment are taken into account,
the actual dose delivered to the target mass (Gy) becomes:
D (in Gy) = [A (in GBq)×50×(1 – [LSF – R ) /M (in kg)
where A is net activity delivered to the liver, D is the radiation absorbed dose to the target liver
mass, M is target liver mass, LSF is lung shunt fraction, and R is percentage residual activity
in the vial[21].
2.2. Resin 90Y microsphere activity calculation
There are two methods for prescribed activity determination provided by the resin micro‐
sphere user’s manual[22] (1) the empiric method and (2) the partition method.
2.2.1. The empiric method
The empiric method recommends a standard amount of activity which is varied only according
to the size of the tumour within the liver. The recommended activity to be implanted for
different degrees of tumour involvement of the liver is as follow:
Tumor <= 25% of the total mass of the liver by CT scan = 2 GBq whole-liver delivery
Tumor > 25% but < 50% of liver mass by CT scan = 2.5 GBq whole-liver delivery
Tumor > 50% of liver mass by CT scan = 3 GBq for whole-liver Delivery
2.2.2. The Body Surface Area (BSA) method
BSA method is a variant of the empiric method that is to adjust the activity implanted according
to the size of the tumor within the liver and the size of the patient. The BSA method is calculated
as follows:
First BSA is calculated from a weight/height chart
BSA(m 2)=0.20247×height(m)0.725 ×weight(kg)0.425
The activity of resin microspheres can be calculated with following formula:
Activity of resin microspheres in
GBq= (BSA−0.2) + volume of tumourvolume of tumour + volume of normal liver
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The BSA method is recommended for patients having concurrent systemic chemotherapy or
for particularly small patients[22].
2.2.3. The partition model
This method involves implanting the highest possible activity to the tumour while maintaining
radiation dose to sensitive tissues such as the lung and the normal liver. The partition model
was developed from basic MIRD methodology to provide an estimate of the radiation dose
separately to tumour and to normal liver. The partition model considers the liver and tumour
to be effectively separate organs from the MIRD point of view. This model relies on accurate
information relating to the degree of lung shunting, liver mass, tumour mass and tissue/normal
(T/N) ratio.
Use of the partition model requires two measurements to be made:
1. measurement of the volume of tumour and normal liver determined from a CT or MRI
scan and
2. measurement of the proportion of Tc-MAA activity that lodges in the tumour, normal
liver and lung.
To determine the T/N the following equation should be used:
T / N = (Atumour / M tumour)Aliver / M liver
Where
A Tumor is the activity in tumor
M Tumor is the mass of tumor
A Liver is the activity in the normal liver
M Liver is the mass of the normal liver
The activity could be calculated as shown by the equation below:
A(GBq)resin =
Dliver({T : N ×M tumour} + M liver)
49670(1− LSF / 100)
Where
D liver = nominal dose (Gy) to the liver
LSF = shunt fraction (%) of microspheres from liver to lung based on MAA scan
M liver = total mass of liver (kg) from CT volume
The partition model has been described in detail in the SIRTex user manual[22].
The activity prescribed can be reduced if the hepatic function is compromised. There is no
consensus guideline regarding the needed rate of reduction in the activity if a patient’s liver
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function or estimated reserve is only just good enough to be a candidate. Generally, more
experienced users reduce dose by 30% for patients with poorer liver function who are still
candidates for this approach according to established eligibility criteria[19]. The amount of
90Y should be also reduced according to the dose adjustment of lung shunt (table 3) if the
percentage lung shunting is greater than 10%[39].
3. Radioembolization
3.2. Complications and side effects
3.2.2. Intrahepatic complications
Before performing the RE some pre medications should be administered.
1. Gastrointestinal (GI) prophylaxis to prevent GI inflammation and ulceration:
Due to the possibility of small unrecognized arterial vessels coursing to the GI system the
routine use of prophylactic antiulcer medications in all patients is recommended. A proton
pump inhibitor (e.g. omeprazole or pantoprazole) or H2-blocker (e.g. ranitidine) commencing
1 week prior to RE and continuing for at least 4 weeks post treatment is to be administered.
2. Anti-nausea prophylaxis
Anti-emetics (e.g. ondansetron or granisetron) are recommended prior to and after RE to
reduce post-treatment nausea.
2. Post embolization syndrome prophylaxis
Fever, malaise and lethargy can occur due to the radiation injury and embolic effect of the RE
on the tumour neo-vasculature. Provided the patient is not diabetic – and oral steroids are not
otherwise contra-indicated – a tapering 5-day steroid dose pack of oral corticosteroids is
recommended. However, this is not a routine practice at all centres.
2. Pain control
Oral analgesia may be required for 1 week following treatment to relieve pain from radiation
injury and the embolic effect of microspheres, as well as liver capsular pain from tumour
edema[22]. Using slow infusion of an i.v. analgesia (e.g. pethidin) and a corticosteroid during
therapy with resin microspheres could be helpful against embolization symptoms.
3.1. Application of the calculated dose
On the treatment day, the calculated activity is injected after confirming the absence of
collateral vessels connecting to the gastrointestinal tract. Administration is performed in an
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angiography suite, primarily by an interventional radiologist. The catheter is usually posi‐
tioned in essentially the same location as that used at arteriography for therapy planning. There
are two different administration sets for application of resin and glass microspheres. The
preparation of these sets and the method of injection have been described in detail in the
respective instructions manuals [22, 32].
During the application direct tracking of microspheres distribution is not feasible and not
required when using glass microspheres. But, it should be performed if resin microspheres are
administered because the resin microspheres have an embolic tendency. In this case the
radiologist must repeatedly check with fluoroscopy to make sure that resin microspheres are
being delivered to the liver and no reflux is occurring back down the artery as this will result
in spillage into other organs such as the stomach and duodenum.
It is highly recommended to perform Bremsstrahlung (BS) scintigraphy up to 24 hours after
application of the microspheres to document the distribution of microspheres within the liver.
Accidental extrahepatic spread of microspheres can also be visualized on post-therapeutic BS
images. In case of adverse events this may allow for a faster diagnosis and early initiation of
treatment. Although whole body and planar BS scans can detect diffuse extrahepatic 90Y
microspheres accumulations in the lungs, intestinal tract or along HFA, their analysis may be
difficult and even misleading due to the low spatial resolution and organ superposition.
Distinguishing between the accumulation of 90Y in the liver and in some adjacent organ
demands the analysis of tomographic images. In a study obtained by our group the sensitivity,
specificity, positive predictive value, negative predicative value and accuracy of SPECT and
SPECT/CT in prediction of GI ulcer were 13 %,88%,8%,92%, 82 % and 87%,100%,100%,99 %,
99% respectively[40].
Overall, the incidence of complications after RE, if patients are selected appropriately and
target delivery is performed meticulously, is low[5]. The complications can be divided into
extrahepatic and intrahepatic.
There is also frequent observation of post embolization symptoms that are not addressed as
complications. It is quite common for patients undergoing RE with resin microspheres to
experience mild post embolization syndrome during the therapy, on the day of treatment and
for up to 1-2 weeks after treatment. These symptoms include fatigue, nausea, and abdominal
pain[19]. The most prominent aspect of post embolization syndrome is fatigue, occurring in
over 50% of the patients[13].
3.2.1. Extrahepatic complications
Serious complications have been reported when microspheres were inadvertently deposited
in excessive amounts in organs other than liver. Reported conditions include gastrointestinal
ulceration/bleeding, gastritis/duodenitis, cholecystitis, pancreatitis, and radiation pneumoni‐
tis [5, 7, 27, 41-43].
Delayed cases of gastroduodenal ulceration were observed despite a standard pre-treatment
evaluation and the contribution of experienced interventional radiologists [31]. These cases
that would be associated with small amounts of Tc-MAA misplaced into the stomach and
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undetected by conventional scintigraphic planar images could have been avoided by the use
of SPECT/CT [34, 44].
One important complication is affection of the non tumorous hepatic parenchyma by radiation.
Cases of veno-occlusive disease, radiation hepatitis and hepatic fibrosis have been described.
To avoid liver complication the therapeutic doses should be adjusted as accurately as possible
and careful dosimetric studies should be carried out. Transient elevation in liver function tests
may occur in patients following RE, specifically a mild increase in alanine transaminase,
alkaline phosphatise and bilirubin[22]. As expected, the likelihood of toxicity is often related
to the patient’s pretreatment liver condition and bilirubin level [5, 21, 45, 46].
3.2.2.1. Radioembolization Induced Liver Disease (REILD)
This mechanism involves the irradiation of normal parenchyma beyond its tolerance (30 Gy)
[47]. REILD is a rare complication of RE,occurring in about 0%-4% of the patients, since this
technique allows the safe delivery of radioactive particles to liver tumours sparing healthy
liver tissue and induce 4-6 times higher tumour absorbed doses from 90Y-microsphere
comparing those to the normal liver tissue[48, 51]. REILD may result in various degrees of
hepatic decompensation and is hard to distinguish from hepatic veno-occlusive disease. In
contrast to radiation induced liver disease from external radiation characterized by sympto‐
matic ascites and elevated liver enzymes but usually not bilirubin, radioembolization-induced
liver disease presents with ascites, usually with non-elevated transaminases (except for ALP
and GGPT), and significant bilirubin increase.
Kennedy et al studied the incidence of REILD after 680 RE with resin microspheres. REILD
was  observed  after  28  treatments  (4%).  Their  data  suggest  an  association  between  the
amount of activity delivered to the patient and REILD [52]. There may also be an associa‐
tion  between  the  use  of  the  empiric  method  for  the  calculation  of  the  dose  (for  resin
microspheres) and toxicity [39].
In another study, age, bilirubin at baseline, treatment approach (whole-liver vs. unilobar), and
the amount of activity administered relative to the total volume treated were found to be
independent risk factors for the development of REILD[53, 54].
To reduce the possibility of REILD, prophylactic administration of corticosteroid, ursodeoxy‐
cholic acid, low-molecular weight heparin, glutamine infusion, prostaglandin-E1, pentoxyfil‐
line and defibrotide may be of benefit [55-57].
High doses of corticosteroids traditionally are administered in an attempt to decrease intra‐
hepatic inflammation. Treatment results are variable and mostly not gratifying, as the
condition progresses in some patients to hepatic insufficiency of various degrees[5]. In most
patients the only treatment needed is the use of diuretics and sodium restriction to maintain
water and sodium balance. Hepatotoxic drugs should be avoided and infections should be
identified and treated promptly.
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4. Follow up
The most appropriate length of follow-up and the time points to technical success are not yet
well defined and follow up schedules vary depending on the treatment plan of each patient.
Continual monitoring of liver function tests is recommended to determine the outcome of
treatment. This includes monitoring for stabilization in liver function tests implying the control
of disease[22]. A biweekly assessment in order to rule out REILD is recommendable in the first
two months after RE.
Abdominal and whole body imaging should be performed for response evaluation as well as
for evaluation of extra hepatic metastases. The frequency and the interval of post-RE imaging
tests should be planned according to the tumour type and individual treatment plan. In our
department patients receive the first post-RE imaging consisted of abdomen MRI and a
metabolic imaging, normally FDG-PET/CT if the HCC was FDG avid, 4 weeks after the
therapy. The next series of imaging are performed 3, 6, 9 and 12 months after therapy unless
there are some other reasons for further imaging studies such as disease progression or
performing other therapies such as chemotherapy.
5. Clinical results of the radioembolization in HCC
All the evidence that supports the use of RE in HCC is based on retrospective series or non-
controlled prospective studies (levels of evidence II-2 and II-3) and no randomized controlled
trials have been published comparing RE with other loco-regional, systemic therapies or best
supportive care[58]. Most series of RE for HCC have reported on the outcome of patients at
different stages that had progressed or relapsed after TACE or were considered poor candi‐
dates for TACE due to the presence of portal vein invasion or bulky tumors.
Geschwind et. al. [59, 60] published a comprehensive analysis on using glass microspheres for
HCC which showed improved survival in Okuda I when compared to Okuda II. In this study
patients classified as Okuda stage I (n= 54) and II (n= 26) had median survival durations and
1-year survival rates of 628 days and 63%, and 384 days and 51%, respectively (P=.02)[60].
In a prospective study on 291 patients, 526 treatments with glass microspheres were performed
and response rates were 42% and 57% based on WHO and EASL criteria, respectively. The
overall time to progression was 7.9 months and survival times differed between Child-Pugh
A and B patients (A:17.2 months, B:7.7 months, P=0.002). Child-Pugh A patients, with or
without PVT, benefited most from treatment and Child-Pugh B patients with PVT had the
worst outcomes[61]. They survived for only 5.6 months (95% CI:4.5–6.7).
In a multicenter analysis 325 patients were treated with a median activity of 1.6 GBq resin
microspheres[62]. Typically, patients were Child-Pugh class A (82.5%) had underlying
cirrhosis (78.5%) and good (ECOG) performance status (ECOG 0-1; 87.7%). Over half of the
patients had advanced BCLC staging (BCLC C,56.3%) and one-quarter had intermediate
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staging (BCLC B, 26.8%). The median overall survival was 12.8 months but varied significantly
between the patients with different disease stages (BCLC A, 24.4 months; BCLC B, 16.9 months;
BCLC C, 10.0 months). Consistent with this finding, survival varied significantly by ECOG
status, hepatic function (Child-Pugh class, ascites, and baseline total bilirubin), tumor burden
(number of nodules, alpha-fetoprotein), and presence of extrahepatic disease. In this study the
most significant independent prognostic factors for survival upon multivariate analysis were
ECOG status, tumor burden (nodules >5), INR >1.2 and extrahepatic disease. Common adverse
events were: fatigue, nausea/vomiting, and abdominal pain. Grade 3 or higher increases in
bilirubin were reported in 5.8% of patients. All-cause mortality was 0.6% and 6.8% at 30 and
90 days, respectively[62].
In a retrospective analysis, Salem et al. [63]compared RE with TACE regarding time to
progression and toxicity. RE resulted in longer time-to-progression and less toxicity in this
study. The survival times of the patients were similar for both treatment modalities, however;
post-hoc analyses of sample size indicated that a randomized study with more than1000
patients would be required to establish equivalence of survival times between patients given
the different therapies.
In a recently published meta analysis of 14 papers, Venti et. al[64] showed almost 80 % any
response (AR =(CR+PR+SD)) for a total of 325 patients with HCC. In this meta analysis
treatment with resin microspheres was associated with a significantly higher proportion of AR
compared to that of glass microsphere treatment (0.89 vs. 0.78 (p=0.02)). Median survival from
RE varied between 7.1 and 21.0 months, and median survival from diagnosis or recurrence
was 9.4– 24.0 months.
In a study of 108 patients with advanced HCC and liver cirrhosis[65] complete responses were
determined in 3% of patients, partial responses in 37%, stable disease 53%, and primary
progression in 6% of patients. Time to progression was 10.0 months and the median overall
survival was 16.4 months.
5.1. Radioembolization of patients with portal vein thrombosis
A compromised portal vein blood flow is usually considered a contraindication for
TACE[66].
Due to the lack of significant macroembolic effect causing liver decompensation, portal vein
thrombosis is not an absolute contraindication to RE. However, patients with main portal vein
thrombosis have a poor prognosis after RE with a median overall survival ranging from 3 to
6 months[67, 68]. On the Contrary, patients with branch (segmentary or lobar) portal vein
thrombosis may achieve an unforeseeable median survival post-RE of 10 to 14 months[67, 69].
5.2. Treating and Downsizing of HCC as a bridging to transplantation or resection
Patients with HCC are only conferred the United Network for Organ Sharing (UNOS) priority
status upgrade if they meet the Milan (T2) criteria [70]. Therefore, if a patient can be down‐
staged from T3 to T2, the immediate advantage is a significant gain in status and therefore
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much quicker access to a potentially life-saving organ. Lewandowski et al.[71] treated 86
patients with either TACE (n = 43) or RE (n = 43). The patients treated with RE achieved a
median dose of 110 Gy. Median tumor size was similar in both groups. Partial response rates
favored RE versus TACE (61% vs. 37%). Downstaging to UNOS T2 was achieved in 31% of
TACE and 58% of RE patients. Time to progression according to UNOS criteria was similar for
both groups. Event-free survival was significantly greater for RE than TACE (17.7 vs. 7.1
months, p =0.0017). Overall survival favored RE compared to TACE (censored 35.7/18.7
months; p = 0.18; uncensored 41.6/19.2 months; p = 0.008). The authors concluded that RE may
outperform TACE for downstaging HCC from UNOS T3 to T2. There was also a significant
difference between these two groups considering the median number of hospitalization days,
being two days for TACE and 0 for RE (p < 0.001)[71].
Author, year n Response rate Median survival
Lau[31], 1998 71 PR:27%, SD:65% 9.4 months
Goin[77], 2005 121 Low risk: 15.5 months
High risk: 3.6 months
Salem[21], 2005 43 PR: 47 % Okuda I: 24 months
Okuda II: 13 months
Young[51], 2007 41 Okuda I: 21.7 months
Okuda II: 14.2 months
Kulik[67], 2008 108 PR: 42%
SD: 35 %
No PVT: 15.4 months
Branch PVT: 10.0 months
Mail PVT: 4.4 months
Inarrairaegui[78], 2010 62 13 months
< 5 nodules: 19 months
> 5 nodules: 8 months
Hilgard[65], 2010 108 CR: 3%
PR: 37 %
SD: 53%
16.4 months
Salem, 2010 291 CR: 23 %
PR: 34 %
BCLC A: 26.9 months
BCLC B: 17.2 months
BCLC C: 7.3 months
BCLC D: 2.5 months
Sangro[62], 2011 325 12.8 months
BCLC A:24.4 months
BCLC B: 16.9 months
BCLC C: 10.0 months
PR: partial response; CR: complete response; SD: stable disease; PVT: portal vein thrombosis;
Table 4. Response rate and median survival of patients with HCC underwent RE
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HCC arising from the caudate lobe is rare and has a poorer prognosis than HCC arising from
the other hepatic lobes[72, 73]. In a retrospective study by Ibrahim et al[74] the effect of RE of
unresectable HCC in caudate lobe was investigated in 8 patients who received a median
radiation dose of 117 Gy. All patients presented with both cirrhosis and portal hypertension.
Four patients were UNOS stage T3. One patient (13%) showed complete tumor response by
WHO criteria, and three patients (38%) showed complete response using EASL guidelines.
Serum AFP decreased by more than 50% in most patients (n = 6, 75%). Four patients (50%)
were UNOS downstaged from T3 to T2, three of who underwent transplantation. One
specimen showed histopathologic evidence of 100% complete necrosis, and two specimens
demonstrated greater than 50% necrosis. Thus, RE seems to be a feasible, safe, and effective
treatment option for patients with unresectable caudate lobe HCC.
Kulik et al.[75] reported a study of 35 patients with T3 unresectable HCC with RE with the
intention of downstaging to resection or RFA. The study showed that RE can be used as a
bridge to transplantation, surgical resection, or RFA. This allows the patients more time to wait
for donor organs and thus increase their chance to undergoing liver transplantation[59]. Post
RE downstaging followed by tumor resection or transplantation provides the possibility of
long-term survival in a select subgroup (UNOS T3 stage) with otherwise limited options[76].
In Table 4 a summary of literatures on RE of HCC with more than 40 patients is demonstrated.
6. Conclusion
RE is a promising treatment modality to achieve regional tumour response and disease control
in HCC. It offers survival benefit with a low toxicity profile. Recent investigations showed
favorable survival outcomes even in patients with limited hepatic reserve and portal vein
thrombosis that were excluded from most therapeutic options. However, Caution regarding
patient selection, treatment preparation and performance is particularly important to prevent
serious toxicity. Improvements in predicting dosimetry will lead to optimization of treatment
outcome even in borderline treatment candidates.
RE has also been successfully used to bridge and downstage patients to resection, ablation or
transplantation. With the sustained accumulation of promising clinical results, RE is moving
forward from the salvage setting indication to the use in earlier stages of metastatic disease.
Clinical trials should further define the precise role of RE in the treatment paradigm.
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